In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara®…
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara®…
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara®…
LEXINGTON, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences…
Exploring new opportunities within the fast-growing market of microfluidics BORDEAUX, France, Feb. 20, 2025 /PRNewswire/ -- Syensqo, a leading specialty…
LAWRENCEVILLE, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its…
Presentation will include an update on the development and launch preparations of Cylembio™ (imsapepimut and etimupepimut, adjuvanted) NEW YORK, Feb.…
Fourth quarter revenue of $168 million and full year revenue of $634 millionFourth quarter orders and revenues sequentially increased 11%…
PharmaJet presentation will highlight the results of recent immunization studies using needle-free intradermal (ID) delivery for polio immunization campaigns. Data…
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Feb. 19, 2025 /PRNewswire/ -- USA News Group News…
